Bacterial Infections Clinical Trial
Official title:
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion as Therapy to Patients With an Infection in the Intensive Care Unit (ICU)
The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared
to non-ICU patients. The investigators will determine total and free flucloxacillin
concentrations in 30 ICU patients, who will get continuous (n=10) or intermittent infusion
(n=20) of flucloxacillin as standard care.
Full pharmacokinetic curves will be taken for individual patients on the intermittent dosing
regimen and limited sampling will be taken for individual patients on the continuous dosing
regimen on day 2 and 4.
The pharmacokinetics of flucloxacillin are expected to be different in ICU patients compared
to non-ICU patients. There is a substantial risk that present standard dosing regimens of
antibiotics lead to suboptimal outcomes for patients on the ICU. To prevent the risk of
inadequate dosing in critically ill patients, it is important to optimize dosing regimens in
ICU patients.
With this study the investigators will define pharmacokinetics of flucloxacillin in ICU
patients and search for variables influencing pharmacokinetics. By using population modeling
the investigators will simulate different dosing regimens, intermittent and continuous, and
compare probability of target attainment between continuous and intermittent infusion.
To be able to include 30 patients within the study duration, a multi-centre approach is
necessary.
Patients will receive standard care, as stated in the product characteristics or according to
local protocols. Minimally invasive blood sampling for pharmacokinetic analysis will be
retrieved through a central venous catheter or an arterial line. Full pharmacokinetic curves
will be taken for individual patients on the intermittent dosing regimen and limited sampling
will be taken for individual patients on the continuous dosing regimen on day 2 and 4.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
| Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
| Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
| Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
| Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
| Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
| Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
| Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
| Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
| Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
| Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
| Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
| Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
| Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
| Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
| Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
| Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
| Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |